本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Achieves International Recognition with HIMSS Award for Excellence in Smart Healthcare TAOYUAN, March 24, 2025 /PRNewswire/ -- As the demand for surgical precision and faster patient recovery continues to grow, smart healthcare has achieved another major breakthrough. Since 2006, Chang Gung Memorial Hospital has pioneered the use of the Da Vinci Robotic Surgical Systems. By the end of 2024, the hospital had performed over 12,000 robotic surgeries, accounting for one-sixth of Taiwan's robotic procedures and cementing its leadership in the field. With its technical expertise and clinical achievements, Chang Gung is steering Taiwan into a new era of minimally invasive surgery worldwide with its robust healthcare system. Chang Gung Memorial Hospital Receives HIMSS Recognition for Pioneering Excellence in Smart Healthcare Chang Gung' s healthcare system has once again captured international attention for its advancements in smart healthcare. At the recent HIMSS (Healthcare Information and Management Systems Society) conference held in Las Vegas, Chang Gung Memorial Hospital, Linkou became the first medical institution in Taiwan to achieve a perfect score in the HIMSS Digital Health Indicator (DHI). The assessment, which measures the digital maturity of healthcare institutions, evaluates "Interoperability", "Person-Centered Healthcare", "Predictive Analytics", and "Governance and Workforce". The accolade highlights Chang Gung's effective integration of smart surgery, data management, and medical AI technologies. New Advances in Single-Port Surgery: Opening New Frontiers in the Treatment of Five Major Cancer Types In 2022, Chang Gung Memorial Hospital became the first medical institution in Taiwan to pass U.S. expert review and obtain approval from the Taiwan Food and Drug Administration (TFDA), enabling the launch of clinical trials for Single-Port Da Vinci Robotic Surgery. This cutting-edge technology focuses on innovative treatments for five major cancer types: breast, prostate, rectal and lung, as well as for thoracic mediastinal tumors. By utilizing only a single incision and combining 3D high-resolution imaging with remote control, the technology aims to minimize trauma, enhance precision, and accelerate recovery. Outstanding Cross-Departmental Collaboration: Delivering Comprehensive Patient Care Chang Gung Memorial Hospital exemplifies the strengths of a leading medical center through its integrated cross-departmental efforts. For instance, the plastic surgery and breast surgery departments have joined forces to advance breast and nerve reconstruction for breast cancer patients. Additionally, the thoracic surgery and plastic surgery teams have jointly completed sympathetic nerve reconstruction (SNR) surgeries, effectively treating hyperhidrosis. These interdisciplinary collaborations provide patients with holistic treatment options and highlight the potential of smart healthcare in various applications. Establishing Asia's Premier Robotic Surgery Training Hub In 2020, Chang Gung Memorial Hospital signed a memorandum of understanding with Intuitive Surgical Inc., the developer of the Da Vinci Surgical System. In 2023, the hospital and the medical equipment maker joined forces to establish the Da Vinci Surgery Training Center at the Chang Gung Surgical Training Academy And Research Center (STARC). To date, the center has hosted 43 advanced training sessions, attracting medical professionals from around the world to observe and learn. The initiative is gradually developing into a hub for robotic surgery education in the Asia-Pacific region. Future Vision: Using AI Analysis Systems to Create a New Era of Digital Surgery Looking ahead, the Chang Gung medical team plans to deploy digital surgery analysis systems developed by global leaders in robotic surgery. Utilizing big data and AI for clinical decision support, combined with cutting-edge medical devices, the hospital is enhancing the efficacy of smart surgery. The approach aims to improve medical outcomes and patient recovery, reflecting the hospital's commitment to patient-centered care.
HONG KONG SAR - Media OutReach Newswire - 29 May 2025 - Hong Kong-based Agilis Robotics has reached a major milestone in surgical innovation with the successful completion of the world's first robotic-assisted en bloc resection of bladder tumour (ERBT) in patients. This clinical trial, conducted with The Chinese University of Hong Kong (CUHK), highlights the Intilume™ System's potential to improve precision and safety in minimally invasive surgeries. Pictured with the Intilume™ System (from left) Professor Kwok Ka-wai, Co-Founder of Agilis Robotics and Professor in the Department of Mechanical and Automation Engineering at CUHK, Professor Ng Chi-fai, Tzu Leung Ho Professor of Urology, and Dr Peter Chiu Ka-fung, Associate Professor in the Division of Urology. The trial, conducted since December 2022, involved eight patients with bladder tumours. All procedures achieved complete tumour removal, and six patients who completed 30-day post-surgery observations showed satisfactory recovery. Two patients remain under observation, with all participants discharged within 1–2 days. The Intilume™ System The Intilume™ System is a robotic surgical platform designed to improve precision and stability in minimally invasive procedures. Featuring two dextrous and miniaturised robotic arms (2.8mm–3.5mm in diameter), it enables accurate en bloc tumour resections in confined spaces. Its intuitive controls can reduce reliance on manual dexterity, shorten the learning curve, and enhance outcomes for complex procedures like ERBT. Conventional resection loop used to perform bladder tumour resection (left) versus the pair of flexible robotic instruments developed by Agilis Robotics (right). Addressing Bladder Cancer Treatment Challenges Bladder cancer is among the 10 most common cancers globally, with 75% of cases being non-muscle-invasive. ERBT is more effective than conventional transurethral resection (TURBT) in reducing recurrence but requires high surgical expertise and carries bleeding and bladder perforation risks. The Intilume™ System improves stability and precision, minimizing these risks. Dr. Peter CHIU Ka-fung, Associate Professor in CUHK's Division of Urology, remarked: "The robotic system increases the stability of ERBT operations, reducing the risks of bleeding and perforation, and enhancing surgical precision. It helps lower the risk of recurrence due to residual tumour tissue and speed up patient recovery. Future Applications The Intilume™ System has potential applications beyond bladder cancer, including gastrointestinal, prostate, uterine, and biliary surgeries. Its compatibility with standard endoscopes and adaptable design makes it a versatile tool across various specialties. This milestone underscores Agilis Robotics' commitment to advancing precision in minimally invasive surgery. Hashtag: #AgilisRobotics The issuer is solely responsible for the content of this announcement.
SHANGHAI, May 23, 2025 /PRNewswire/ -- Shanghai UniXell Biotechnology Co., Ltd. (UniXell Biotech), a biotech company dedicated to innovative cell therapies, announced the successful first administration of its proprietary Parkinson's disease cell drug UX-DA001 in China in March 2025. The Phase I clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of UX-DA001 in patients with Parkinson's disease. On March 1, 2025, Dr. Li Dianyou, Director of the Functional Neurosurgery Department at Ruijin Hospital, performed the surgical path planning and the subsequent stereotactic surgery for transplantation. The successful surgery marks the official initiation of China's first registration-directed clinical trial for an autologous iPSC-derived cell therapy for Parkinson's disease. The one-month postoperative follow-up revealed significant improvements in the patient's sleep quality and motor function, with no severe adverse events reported. The first recipient of UniXell's autologous stem cell-derived drug, UX-DA001, shared, "after receiving the stem cell treatment, I experienced a remarkable improvement in my sleep quality. I fall asleep quickly and notice gradual progress every day. Although recovery takes time, the 'day by day improvement' fills me with hope for the future." Dr. Liu Jun, Principal Investigator of the trial and Director of the Neurology Department at Ruijin Hospital, noted "current standard treatment for Parkinson's disease primarily relies on medications to alleviate symptoms. However, after prolonged oral drug treatment, patients often experience fluctuations in efficacy and disease progression continues. In contrast, cell therapy offers the prospect of 'one-time treatment with long-term benefits.'" About UX-DA001 and Phase 1 Trial UX-DA001 is an investigational autologous iPSC-derived neural progenitor cell drug. It is derived from the patient's own peripheral blood cells, which are firstly reprogrammed into induced pluripotent stem cells and then differentiated into dopaminergic neurons in vitro. It is then transplanted into the patient's brain through a minimally invasive surgery. UX-DA001 leverages the patient's own cells, significantly reducing the risk of immune rejection. Patients do not require immunosuppressive drugs, thereby avoiding potential side effects such as increased infection and tumor risks, organ toxicity, and metabolic disorders, thus achieving a safer and more effective treatment that significantly improves the quality of life for patients. The UX-DA001 has received clinical trial approvals (Investigational New Drug, IND) from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA) in December 2024 and February 2025, respectively, offering UX-DA001 a potential to have implications on patients with Parkinson's disease in not only China but also globally. The phase 1 study is conducted at Ruijin hospital in Shanghai, China, under the guidance of Dr. Liu Jun, MD, PhD, Principal Investigator (PI). The transplantation is performed by Dr. Li Dianyou, the director of the Functional Neurosurgery Department. This clinical study is designed to evaluate the safety and tolerability of UX-DA001 cell transplantation. It also investigates whether the transplanted cells survive, integrate and improve motor function in subjects with Parkinson's disease. More information about this trial is available at clinicaltrials.gov (NCT#06778265). About UniXell Biotechnology Co., Ltd. Shanghai UniXell Biotechnology Co., Ltd. was established in 2021, specializing in the research and development of cell therapy drugs for neurological diseases, including Parkinson's disease and epilepsy. In addition to its autologous UX-DA001, UniXell`s IND application for UX-DA002, an allogenic cell therapy for Parkinson`s disease, has been recently accepted by NMPA. The company is equipped with a 4000 m2 R&D center and GMP facilities. It has developed four major innovative technology platforms based on reprogramming technology, stem cell differentiation technology, SISBAR lineage tracing technology, and high-precision gene editing. These platforms facilitate the development and production of neural cell drugs with higher purity and more stable efficacy, ensuring efficient and safe clinical treatment outcomes. As of the present, UniXell has successfully obtained several rounds of funding from esteemed investors, such as Hillhouse Capital, CDH Investments, Fosun Group, Sherpa Healthcare Partners, TF Capital, and Tianshi Capital, among others. This underscores the robust market confidence in its pioneering therapeutic solutions and its potential for growth. Contact: UniXell Biotechnology Co., Ltd.business@unixell.com
SHANGHAI, Feb. 17, 2025 /PRNewswire/ -- Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independent research and external collaborations, thereby driving transformation and development in the pharmaceutical industry through technological advancements. At the same time, Fosun Pharma is accelerating the deeper application of AI technology in marketing, customer service, and smart office solutions, using AI to improve quality and efficiency while promoting enhanced corporate management effectiveness. Fosun Pharma's Layout in AI Field Self-developed PharmAID Decision Intelligence Platform Integrates Global Leading Large Model Technology and Has connected with Deepseek R1 As a pioneer in the AI transformation of the pharmaceutical industry, Fosun Pharma recently launched its self-developed PharmAID decision intelligence platform internally. This platform establishes a full lifecycle intelligent decision-making network covering innovative R&D scenarios. Deeply integrated with global leading large model technologies, the platform has taken the lead in connecting to with Deepseek R1. Based on the PharmAID decision intelligence platform, Fosun Pharma is accelerating the development of "drug commercial value-assisted decision-making" capabilities, broadening decision-making perspectives, and improving decision accuracy. The platform enhances drug R&D efficiency and accelerates the transformation of R&D achievements by integrating point prediction, conformational prediction, binding mechanism analysis, toxicology optimization, medical writing, and clinical information extraction. This initiative aims to lead innovation and transformation, and it is the first self-developed AI decision intelligence platform in pharmaceutical industry. The PharmAID decision intelligence platform offers AI translation and AI medical writing/revision features, significantly improving information retrieval and writing efficiency under the support of AI technology. At present, the PharmAID decision intelligence platform has integrated multiple professional clinical information and pipeline data platforms around the world, increasing content generation accuracy in the pharmaceutical and healthcare field by 50% compared to general large models, with data updated at T+1, ensuring outstanding accuracy and timeliness. Moreover, Fosun Pharma applies AI technology to carry out intelligent training for sales personnel and further assists business scenarios, achieving "more precise" marketing. Through the deep empowerment of the PharmAID decision intelligence platform, Fosun Pharma is building its digital competitiveness, leading the entire pharmaceutical industry into a new era of AI-driven innovation. AI Technology Empowers Innovative R&D and Accelerate Breakthroughs Fosun Pharma actively promotes AI-driven innovation. As early as 2022, Fosun Pharma formed a strategic partnership with AI pharmaceutical company Insilico Medicine, combining strengths to embark on a new journey in global AI drug R&D. In January 2025, Henlius, a subsidiary of Fosun Pharma, entered into a strategic collaboration with DP Technology for AI-assisted drug R&D, aiming to integrate AI with physical modeling to jointly advance new drug development processes. This collaboration leverages DP Technology's technical strength and project experience in the "AI for Science" field, combining expertise in drug discovery and AI computing to provide new insights for the development of biologics antibodies/ADCs and small molecule drugs targeting difficult-to-drug targets. Building an "AI+X" Smart Healthcare Ecosystem In medical devices sector, Fosun Aitrox, a subsidiary of Fosun Pharma, focuses on the medical AI field and is one of the few companies in China offering comprehensive AI medical service solutions across multiple departments including radiology, pathology, ultrasound, cardiology, respiratory, orthopedics, neurology, and thyroid and breast surgery. Fosun Aitrox delves into medical institutions and primary healthcare service scenarios, identifying real needs and enhancing service capabilities in core scenarios of tiered healthcare systems, including early screening, remote diagnosis, and precision medicine. Through the "AI+X" model, Fosun Aitrox collaborates deeply with top medical centers, promoting the transformation of scientific research achievements and the popularization of standardized medical systems, empowering the construction of smart diagnosis and treatment systems. Its three major AI-assisted diagnostic product lines—radiology imaging, pathology imaging, and ultrasound imaging—have been widely used clinically and have won multiple world championships in international competitions. Fosun Aitrox's AI medical imaging products can quickly and accurately analyze medical imaging data, providing doctors with diagnostic suggestions, helping them more efficiently identify lesions and assess conditions, thereby improving diagnostic accuracy and timeliness. The application of this technology not only enhances the quality and efficiency of medical services but also benefits patients in remote and resource-scarce areas, allowing them to access high-quality medical services locally. To date, Fosun Aitrox has expanded its presence to cover 70% of China, with operating businesses in over 20 provinces, establishing nearly 10 regional smart healthcare project models. The company has released and is developing more than 70 AI products. Additionally, Fosun Pharma's incubated company, JeDiCare, leverages its extensive experience in image navigation algorithm development and interventional consumable design, along with a global perspective, to innovatively introduce AR navigation technology into minimally invasive surgery. Its self-developed puncture surgery navigation device (AR navigation puncture positioning system) is currently under market application review. This product features proprietary "monocular vision augmented reality" technology, integrating computer vision monocular tracking and AR display technology, not only achieving precise positioning but also optimizing the positioning process. In the future, with the assistance of the AR navigation puncture positioning system, primary hospitals will also be able to perform precise thoracoscopic surgeries, bringing high-quality medical care to more patients. Looking ahead, Fosun Pharma will continue to increase investment and exploration in AI, accelerating the construction of AI innovation across the entire industry chain through independent research and external collaborations, leading the AI transformation of the pharmaceutical industry, and contributing more wisdom and strength to the cause of human health. *** About Fosun Pharma Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and unmet clinical needs-oriented. Through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and industrial investment, the company continues to enrich its innovative product pipeline and focus on differentiated product R&D with high-tech barriers, to continuously enhance the value of its pipeline. Fosun Pharma's innovative products focus on core therapeutic areas such as solid tumors, hematologic tumors and immunity inflammation. It also strengthens core technology platforms such as antibodies/ADC, cell therapy, and small molecules. Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma adheres to the business philosophy of "Innovation for Good Health", continues to promote innovative transformation, actively deploys internationalization, strengthens business focus by product lines, promotes integrated operations and efficiency improvement, and is dedicated to being the global leading integrator of pharmaceutical and healthcare innovation. For more information, please visit our official website: www.fosunpharma.com
SUBANG JAYA, Malaysia, Jan. 23, 2025 /PRNewswire/ -- Sunway Medical Centre, Sunway City (SMC), has been honoured in the inaugural Newsweek's Top Private Hospitals 2025 ranking and recognised as the top hospital in Malaysia for four out of five procedures: knee surgery and knee replacement, shoulder surgery, cataract surgery, and eye refractive surgery. (From left) Dato Lau Beng Long, Sunway Healthcare Group President; Dr Jeffrey Jaya Raj, Head of Orthopaedic Department, Sunway Medical Centre, Sunway City (SMC); Dr Peh Khaik Kee, Clinical Head of Ophthalmology, SMC; Dr Low Kwai Siong, Medical Director, SMC; Tan Mei Shin, Senior Director of Business Development & Corporate Communications; SMC; Choong Sui Ching, General Manager of Orthopaedic Services, SMC Additionally, it is ranked 2nd in Asia for cataract surgery, and 3rd in Asia for refractive eye surgery. SMC is also featured in the top 10 of Asia's ranking for hip surgery and hip replacement (6th); knee surgery and knee replacement (6th); and shoulder surgery (10th). "We are honoured to be ranked among the best in Asia for key specialities such as orthopaedics and ophthalmology. It is a testament to our relentless pursuit of clinical excellence. "The recognition also underscores the dedication of medical specialists and other healthcare professions in providing a high standard of multidisciplinary care and treatment to our Malaysian and international patients," said Dato' Lau Beng Long, President of Sunway Healthcare Group. As Malaysia's largest private quaternary hospital, SMC is the first hospital in Malaysia to obtain three major hospital-wide accreditations: Joint Commission International (JCI) Accreditation, The Gold Seal of Approval from the United States; the Australian Council on Healthcare Standards (ACHS); and the Malaysian Society for Quality in Health (MSQH). The hospital offers 28 Centres of Excellence, supported by a diverse multidisciplinary team that provides holistic and personalised treatment. Sunway Eye Centre, one of SMC's Centres of Excellence, offers services across various subspecialties including cataract and refractive ophthalmology, cornea transplant, medical retinal and uveitis, glaucoma, oculoplastic ophthalmology, and paediatric ophthalmology. SMC's Orthopaedic Centre, together with Robotic Surgery and Minimally Invasive Surgery (MIS) Centre, have achieved remarkable milestones, especially in robotic hip and knee replacement surgeries, which earned recognition in the Malaysia Book of Records. This achievement underscores the centre's expertise and unwavering commitment to innovation. This latest rankings builds on SMC's success in the Newsweek World's Best Hospitals 2024 rankings, where it was named one of the top 250 hospitals globally. The hospital was also featured in Newsweek's Best Specialist Hospitals Asia Pacific list for two consecutive years, 2023 and 2024.
LAS VEGAS - Media OutReach Newswire - 6 January 2025 - Innolux will showcase its latest, most innovative product technologies in Las Vegas, U.S.A. from January 7 to 9 under the theme "Driving New Possibilities". James Yang, President of Innolux, said that Innolux has added yet more value to its display field, created outstanding innovative technologies, and crafted comprehensive scenario-tailored service solutions, exporting these boons to overseas markets. Technology-wise, AI software and hardware come together to invent new solutions. Innolux products span multiple application fields like retail, healthcare, entertainment, mobility, and others, to comprehensively elevate convenience, safety, and fun, as well as embrace all-around smart technology in everyday life, leading us into the future. Innolux exhibits smart dimming sun visor Industry's First Color-Conversion-Based AM MicroLED Technology Delivers New Value in Display Technology Innolux has been deeply involved in forward-looking panel technology for many years and showcased the industry's first 106" Color-Conversion-Based AM-MicroLED Free Tiling Display with six main features: lifelike high resolution, high color saturation, wide color gamut, excellent ambient light contrast, seamless tiling, and low power consumption. Extremely small pixel pitch (≦P0.6mm) achieves a new level of ultra-high definition all across the screen. Its color-conversion-based microLED and flawless free tiling panel module comes in 12.3" to 220" based on customer needs. The limitations of traditional panels are transcended to realize an unparalleled high-end, high-definition, and ultra-large visual experience. Innolux's free tiling QD color-conversion-based MicroLED display technology employs an active TFT driving backplane and has a four-sided tileable design. It is also equipped with a full-color solution for color conversion technology powered via blue LED chips with quantum dots. It is able to overcome two major problems of RGB MicroLED technology architecture, including the lack of uniformity typical of green LED chips and the poor efficiency and reliability of red LED chips after miniaturization. It can also significantly reduce the number of massive transfers, thereby lowering costs and improving yields. Furthermore, the use of high-performance color conversion materials can also achieve a wide color gamut of BT2020 with 90% area ratio. In addition, Innolux debuted its innovative 9.6" AM-MicroLED Mirror Display, which features ultra-high brightness (1200 nits), ultra-high contrast (1,000,000:1), wide color gamut (NTSC 120%), and ultra-high reflectivity, and energy saving, among other astounding advantages. MicroLED Smart Mirror is an integrated multi-functional smart mirror display. It is equipped with automotive-grade RGB self-luminous MicroLED technology. Its tiny aperture area ratio can provide visuals with high reflectivity and ultra-high brightness while ensuring low power consumption. Similar in appearance to a 9.6" mirror, the smart mirror display combines exclusive pioneering display technology to not only show product information, promotional messages, and personalized advertisements, but also enable consumers to enjoy an interactive VR experience. This emerging display technology will provide comprehensive system solutions for smart retail, smart cockpit, and other fields. With its robust and forward-looking MicroLED technology, Innolux has obtained nearly 580 patents approved by the U.S.A. Its excellent display quality and market potential cannot be understated. Innolux has repeatedly garnered much technical praise and recognition at international expos and national display technology awards. Our products offer many excellent features such as high image quality, seamless and free tiling, fast response, low power consumption, and ultra-power saving. Application scenarios include smart education, high-end theaters, museums, and other 8K retina large-scale display markets, as well as smart mobile, smart retail, and many other diverse avenues for innovation. Innolux spares no effort to deliver new value in the display sector. Next-Gen MiniLED display Technology Revolutionizes Outdoor Public Panel Market and Ushers in a New Visual Era In view of increasing demand for smart cities and outdoor panels, Innolux is committed to delivering value-added innovation in panels, successfully revolutionizing next-gen miniLED technology and breaking through the limitations of traditional backlight panels. Innolux's latest 17.3" and 23.8" miniLED Sunlight Readable Display leverages miniature, efficient LED dot matrix technology to not only achieve excellent outdoor visibility under the sun, but also maintain low power consumption while providing an excellent performance that ensures high brightness, high contrast, and wide color gamut. This breakthrough technology allows the panel to remain clearly visible even in outdoor environments with strong light. It can accurately perform real-time dynamic zoning adjustments based on the content shown, rendering deeper dark hues and outstanding contrast to present vibrant images with rich, detailed layers. Embrace the ultimate visual enjoyment with the most dynamic, exhilarating image quality. Innolux's miniLED panels are widely used in various outdoor sports events, commercial retail, cultural events and shows, and other domains. In the future, we plan to further expand into special application scenarios such as digital signage, charging piles, large department stores, shopping malls, and navigation. Our panels can also deliver unparalleled visibility and functionality while meeting the needs of different environments. In addition, Innolux also showcased the 14" QHD+ Ultra-Thin Display, which combines a lightweight body with vivid color rendering. In addition to reducing module weight, it is equipped with 100% DCI-P3 wide color gamut technology, tailormade for the mobile commerce market to perfectly satisfy the needs of students and business people in mobile offices. Innolux has also actively launched the 14" and 16" FHD+ Touchscreens that support finger touch operations and can be integrated with the latest AI technology to realize participatory and interactive learning courses, significantly enhancing the interactivity and creative expression in education scenarios. These touchscreens make the learning process more interesting, effectively lower the learning threshold through multi-sensory engagement, and stimulate students' creativity and passion for learning. Pupils are assisted to understand lessons more deeply and they're even able also to draw, sketch, or take notes conveniently to become more motivated and enhance their learning outcomes. Exclusive LC Dimming Technology to Seize Smart Car Market and Achieve Environmental Sustainability for a Green Future Carbon reduction and the goal of net zero are about more than sustainability: they are an essential requirement for global corporations to transform and create competitive value. Global warming is a challenge that all sectors and nations must tackle jointly. Cities, in particular, are some of the main arenas for implementing carbon reduction and accomplishing net zero. Innolux is committed to implementing value transformation through the guiding principle "More than Panel", actively engaging in non-panel application fields. By harnessing our exclusive liquid crystal film technology and glass integration process capabilities, Innolux is pioneering advanced applications for Smart LC Windows. Innolux's smart city solution, Smart LC Windows, is equipped with the advantages of high transparency, energy saving and consumption reduction, fast response time, intelligent network connection, and more. It can not only cater to sustainable smart green buildings, but also suits applications in the wider automotive field. We actively integrate LC dimming technology in automotive component products such as smart dimming windows, smart dimming rear-view mirrors, and smart dimming sun visors to foster green business opportunities, create new industry possibilities, and practice environmental sustainability, thereby pursuing a green future. Innolux's groundbreaking smart dimming window effectively solves window tint's limitation of only allowing one type of light transmission. Moreover, the smart dimming rear-view mirror automatically senses light intensity in the surroundings and adjusts reflectivity according to the driver's requirements to ensure that they can clearly observe traffic conditions in the rearview under different lighting, thereby greatly improving driving safety and comfort. Last but not least, the smart dimming sun visor also dynamically adjusts the light transmittance of the sun visor in real time based on the intensity of external light. Besides protecting the driver's vision from strong light, this innovative design also prevents blind spots caused by traditional sun visors, thus providing a safer and more comfortable driving experience. Next-Gen Immersive 3D Experience As the AI wave drives up the demand for new-generation 3D stereoscopic panels, Innolux is committed to converting flat display into stereoscopic immersive 3D screens. Our 27" N3D Eyetracking adopts the world's unique N3D display technology and its low-crosstalk algorithm delivers a high-quality 3D visual experience, greatly ameliorating the pain point of dizziness caused by long-term use. The exclusive algorithm renders 3D in real time without taking up computational resources. Its excellent display technology brings e-sports players marvelous 3D visual enjoyment as if they were transported to their favorite scenes. Innolux's N3D technology not only delivers the best immersive experience to users in the fields of videogames and entertainment. In terms of medical and educational applications, its excellent light field 3D technology, eye tracking technology, low latency, and other advantages can offer a comprehensive solution for medical imaging, providing a more efficient and intuitive interactive teaching experience in preoperative planning, lesion assessment, minimally invasive surgery, and even medical teaching. Hashtag: #Innolux The issuer is solely responsible for the content of this announcement.
A12 藝術空間
minimally invasive surgery
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
